Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on May 18, 2022. The company is an emerging growth company incorporated in Nevada with principal executive offices in Boca Raton, Florida. Its common stock trades on The NASDAQ Stock Market LLC under the symbol "INMB."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain financial statements or performance data.
Material Changes
No material financial changes or operational updates were reported in this filing. The document solely announces a scheduled corporate presentation.
Guidance, Outlook, and Management Commentary
David Moss, Chief Financial Officer, is scheduled to present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference on May 24, 2022, at 10:00 a.m. Eastern Time. The press release regarding this event is attached as Exhibit 99.1. The filing explicitly states that the information contained herein shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other registration statements unless expressly set forth by specific reference.
Investor Verification Checklist
- Verify the date and time of the H.C. Wainwright Global Hybrid Investment Conference presentation (May 24, 2022, 10:00 a.m. ET).
- Review the attached press release (Exhibit 99.1) for specific details on the corporate overview.
- Confirm that no financial data or material risk factors were disclosed in this specific 8-K filing.
- Note the legal disclaimer regarding the non-filing status of the information for liability purposes under Section 18 of the Exchange Act.